Unilabs subholding announces pricing of its senior notes offering Skip to main content

Media Release

20 May 2017

Unilabs subholding announces pricing of its senior notes offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA 

  
Unilabs subholding announces pricing of its senior notes offering

 LONDON —20 April 2017

Unilabs SubHolding AB (publ) (the “Issuer”) today announced that it has priced its offering of €250,000,000 aggregate principal amount of 5.75% senior notes due 2025 (the “Notes”). The offering is expected to close on May 5, 2017. The proceeds from the offering, if completed, will be used, to (i) provide a portion of the permanent financing for the previously announced and recently completed acquisition of Alpha Medical, a leading medical diagnostics company serving customers in Slovakia and the Czech Republic, (ii) redeem in full the outstanding amount of €125,000,000 aggregate principal amount of 11.5%/12.5% second lien PIK toggle notes due 2022 issued by Unilabs MidHolding AB (publ), the direct parent of the Issuer, and (iii) pay certain fees and expenses in connection with the foregoing.

 Cautionary Statement

The Notes will be offered only to qualified institutional buyers pursuant to Rule 144A and outside the United States pursuant to Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”). There is no assurance that the offering will be completed or, if completed, as to the terms on which it is completed. The Notes to be offered have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or unless pursuant to an applicable exemption from the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This announcement does not constitute and shall not, in any circumstances, constitute a public offering nor an invitation to the public in connection with any offer within the meaning of the Directive 2003/71/EC of the Parliament and Council of November 4, 2003 as implemented by the Member States of the European Economic Area, as amended from time to time (the “Prospectus Directive”). The offer and sale of the Notes will be made pursuant to an exemption under the Prospectus Directive, as implemented in Member States of the European Economic Area, from the requirement to produce a prospectus for offers of securities.

In connection with the issuance of the Notes, one of the initial purchasers (or persons acting on their behalf) will serve as stabilizing manager and may over-allot the Notes or effect transactions with a view to supporting the market price of the Notes at a level higher than that which might otherwise prevail. However, there is no assurance that the stabilizing manager (or persons acting on behalf of the stabilizing manager) will undertake stabilization actions. Any stabilization action may begin on or after the date on which adequate public disclosure of the final terms of the offer of the Notes is made and, if begun, may be ended at any time, but it must end no later than the earlier of 30 calendar days after the issue date of the Notes and 60 calendar days after the date of the allotment of the Notes. Any stabilization action or over-allotment must be conducted in accordance with all applicable laws and rules.

Forward-Looking Statements

This press release may include forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will” or “should” or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts and include statements regarding the Unilabs group or its affiliates’ intentions, beliefs or current expectations concerning, among other things, the Unilabs group or its affiliates’ results of operations, financial condition, liquidity, prospects, growth, strategies and the industries in which they operate. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and that the Unilabs group or its affiliates’ actual results of operations, financial condition and liquidity, and the development of the industries in which they operate may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if the Unilabs group or its affiliates’ results of operations, financial condition and liquidity, and the development of the industries in which they operate are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods.

About Unilabs

With 112 clinical laboratories and 44 imaging units and a broad catalogue of more than 2,500 diagnostic tests, Unilabs is one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services. Headquartered in Geneva, the Unilabs group services sectors ranging from private and public healthcare providers to local governments, from pharmaceutical companies to the general public. The company employs more than 5,200 employees worldwide, successfully operating laboratory, medical diagnostic imaging facilities or commercial presence in 14 countries, and generating annual revenues of approximately €680 million in 2016. Its network of facilities provides its customers with one of the broadest geographic footprints of any clinical laboratory and medical diagnostic services provider in Europe.

 We are at the heart and start of all effective treatment decisions: www.unilabs.com

Welcome to the Unilabs Website

Continue to the main Corporate Website

OR: Select a Unilabs Country Website from the list below